Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

F J Dumont

Showing results (1-10 of 65) with videos related to

Pageof 7
Sort By:
Journal of Interferon Research|June 1, 1988
Recombinant human interferon-alpha A/D enhances the expression of Ly-6A/E, Ly-6C, and TAP antigens on murine T lymphocytesF J Dumont
Current Opinion in Investigational Drugs (London, England : 2000)|September 29, 2001
Treatment of transplant rejection: are the traditional immunosuppressants good enough?F J Dumont
Journal of Immunology (Baltimore, Md. : 1950)|June 15, 1987
Stimulation of murine T cells via the Ly-6C antigen: lack of proliferative response in aberrant T cells from lpr/lpr and gld/gld mice despite high Ly-6C antigen expressionF J Dumont
Current Opinion in Investigational Drugs (London, England : 2000)|November 23, 2001
Everolimus. NovartisF J Dumont
Cellular Immunology|April 1, 1987
Divergent effects of cyclosporine A on interferon- and mitogen-induced Ly-6A antigen suggest autocrine regulation of Ly-6A expression in activated T cellsF J Dumont
International Archives of Allergy and Immunology|November 18, 1997
FK506 enhances IL-13 production by T cells activated through CD3/CD28F J Dumont
Current Opinion in Investigational Drugs (London, England : 2000)|August 31, 2001
Alemtuzumab (Millennium/ILEX)F J Dumont
Current Medicinal Chemistry|March 7, 2000
FK506, an immunosuppressant targeting calcineurin functionF J Dumont
Idrugs : the Investigational Drugs Journal|August 23, 2005
BMS-188667 (Bristol-Myers Squibb)F J Dumont
Cellular Immunology|September 1, 1986
Treatment of resting T lymphocytes with interferon-alpha/beta augments their proliferative response to activation signals delivered through their surface Ly-6 antigenF J Dumont
Pageof 7

Showing results (1-10 of 65) with videos related to

Sort By:
Pageof 7
Journal of Interferon Research|June 1, 1988
Recombinant human interferon-alpha A/D enhances the expression of Ly-6A/E, Ly-6C, and TAP antigens on murine T lymphocytesF J Dumont
Current Opinion in Investigational Drugs (London, England : 2000)|September 29, 2001
Treatment of transplant rejection: are the traditional immunosuppressants good enough?F J Dumont
Journal of Immunology (Baltimore, Md. : 1950)|June 15, 1987
Stimulation of murine T cells via the Ly-6C antigen: lack of proliferative response in aberrant T cells from lpr/lpr and gld/gld mice despite high Ly-6C antigen expressionF J Dumont
Current Opinion in Investigational Drugs (London, England : 2000)|November 23, 2001
Everolimus. NovartisF J Dumont
Cellular Immunology|April 1, 1987
Divergent effects of cyclosporine A on interferon- and mitogen-induced Ly-6A antigen suggest autocrine regulation of Ly-6A expression in activated T cellsF J Dumont
International Archives of Allergy and Immunology|November 18, 1997
FK506 enhances IL-13 production by T cells activated through CD3/CD28F J Dumont
Current Opinion in Investigational Drugs (London, England : 2000)|August 31, 2001
Alemtuzumab (Millennium/ILEX)F J Dumont
Current Medicinal Chemistry|March 7, 2000
FK506, an immunosuppressant targeting calcineurin functionF J Dumont
Idrugs : the Investigational Drugs Journal|August 23, 2005
BMS-188667 (Bristol-Myers Squibb)F J Dumont
Cellular Immunology|September 1, 1986
Treatment of resting T lymphocytes with interferon-alpha/beta augments their proliferative response to activation signals delivered through their surface Ly-6 antigenF J Dumont
Pageof 7